Evidence map›Paper›PMID 39135965›Full record

ArticleOpen forum infectious diseases2024

Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection.

Justine Abella Ross, Brian Lee, Huiyan Ma, Bernard Tegtmeier, Deepa Nanayakkara, Jana Dickter, Ricardo Spielberger, Eileen Smith, Vinod Pullarkat, Stephen J Forman and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Justine Abella RossDepartment of Pharmacy, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0001-8661-6380
Brian LeeDepartment of Pharmacy, City of Hope National Medical Center, Duarte, California, USA.
Huiyan MaDivision of Biostatistics, Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, California, USA.
Bernard TegtmeierDepartment of Quality Risk and Regulatory Management, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0002-3704-1733
Deepa NanayakkaraDivision of Infectious Disease, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0002-4310-3275
Jana DickterDivision of Infectious Disease, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0001-5579-1573
Ricardo SpielbergerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0002-8887-6482
Eileen SmithDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Vinod PullarkatDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0001-9129-3424
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0002-2803-4152
Randy TaplitzDepartment of Medicine, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0002-0109-5991
Ryotaro NakamuraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Monzr Al MalkiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0001-8226-471X
Sanjeet Singh DadwalDivision of Infectious Disease, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0002-1099-0568

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Continuing antifungal prophylaxis (AFPx) to prevent invasive mold infections (IMIs) in recipients of allogeneic hematopoietic cell transplantation (alloHCT) after primary hospital discharge from alloHCT admission varies among transplant centers despite recommendations to continue prophylaxis through day +75. Characteristics driving AFPx prescribing at hospital discharge and outcomes are unknown. Methods: In this retrospective analysis, we reviewed patients continuing AFPx vs no AFPx at hospital discharge. We included patients with a hospital stay ≥7 days and ≤40 days. We excluded patients with a history of IMI prior to alloHCT, new IMI during admission, or death prior to discharge. Our primary objective was incidence of probable or proven IMI per the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Our secondary objectives were nonrelapse mortality at day +100, overall survival at day +100, and characteristics driving AFPx discontinuation at hospital discharge. Results: Of the 430 patients identified, 387 met inclusion criteria. At discharge, 56% (217/387) continued AFPx, and 44% (170/387) had no AFPx. At day +100, 3 probable IMI cases occurred in the group with continued AFPx vs 1 probable IMI case in the no-AFPx group (no proven IMI). Univariate analysis showed no difference in cumulative incidence of probable IMI ( Conclusions: There was no difference in probable IMI at day +100 after alloHCT based on continuing vs discontinuing AFPx at hospital discharge after alloHCT admission supporting a risk-adapted prophylaxis approach.

Indexed as

antifungalhematopoieticinvasive mold infectionprophylaxistransplant

Identifiers

PMID39135965
PMCPMC11317840

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.